Advanced Biomed Inc. is a biotechnology holding company focused on developing microfluidic biochip technologies for precision oncology applications. It integrates semiconductor technology and biotechnology to create advanced diagnostic tools, including devices such as A+Pre for automated sample preparation, AC-1000 for rare cell detection in tumor patient samples, A+SCDrop for single circulating tumor cell capture, and A+CellScan for immunostaining analysis. Corresponding microfluidic biochips and immunostaining kits like A+CTCE, A+CTCM, A+EMT, and A+CM enable the detection of circulating tumor cells and tumor markers in blood samples. These products support early cancer screening, diagnosis, staging, treatment selection, and prognosis through liquid biopsy techniques, including single-cell sorting. The company also offers the A+LCGuard kit for lung cancer early screening and operates medical clinics in China. Primary operations, research, and development occur via its Taiwan subsidiary in Tainan, with a Hong Kong entity handling China market activities including localized production and sales, and a Shanghai subsidiary managing clinical trials. Founded in 2014 and headquartered in Tainan, Taiwan, Advanced Biomed Inc. provides rapid, affordable assay products and services to cancer patients worldwide.